177 related articles for article (PubMed ID: 36681883)
1. A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses.
Morrison JI; Metzendorf NG; Rofo F; Petrovic A; Hultqvist G
J Neurochem; 2023 May; 165(3):413-425. PubMed ID: 36681883
[TBL] [Abstract][Full Text] [Related]
2. Standardized Preclinical
Morrison JI; Petrovic A; Metzendorf NG; Rofo F; Yilmaz CU; Stenler S; Laudon H; Hultqvist G
Mol Pharm; 2023 Mar; 20(3):1564-1576. PubMed ID: 36808999
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease.
Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G
Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433
[TBL] [Abstract][Full Text] [Related]
4. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Metzendorf NG; Wik E; Roshanbin S; Julku U; Chourlia A; Nilsson P; Andersson KG; Laudon H; Hultqvist G; Syvänen S; Sehlin D
Alzheimers Res Ther; 2023 May; 15(1):90. PubMed ID: 37131196
[TBL] [Abstract][Full Text] [Related]
6. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
[TBL] [Abstract][Full Text] [Related]
7. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
8. Introducing or removing heparan sulfate binding sites does not alter brain uptake of the blood-brain barrier shuttle scFv8D3.
de la Rosa A; Metzendorf NG; Morrison JI; Faresjö R; Rofo F; Petrovic A; O'Callaghan P; Syvänen S; Hultqvist G
Sci Rep; 2022 Dec; 12(1):21479. PubMed ID: 36509864
[TBL] [Abstract][Full Text] [Related]
9. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
10. Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies.
Faresjö R; Lindberg H; Ståhl S; Löfblom J; Syvänen S; Sehlin D
Pharm Res; 2022 Jul; 39(7):1509-1521. PubMed ID: 35538266
[TBL] [Abstract][Full Text] [Related]
11. Nogo-A neutralization in the central nervous system with a blood-brain barrier-penetrating antibody.
Joly S; Augusto G; Mdzomba B; Meli I; Vogel M; Chan A; Pernet V
J Control Release; 2024 Feb; 366():52-64. PubMed ID: 38154541
[TBL] [Abstract][Full Text] [Related]
12. Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.
Hultqvist G; Syvänen S; Fang XT; Lannfelt L; Sehlin D
Theranostics; 2017; 7(2):308-318. PubMed ID: 28042336
[TBL] [Abstract][Full Text] [Related]
13. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.
Faresjö R; Bonvicini G; Fang XT; Aguilar X; Sehlin D; Syvänen S
Fluids Barriers CNS; 2021 Jun; 18(1):26. PubMed ID: 34078410
[TBL] [Abstract][Full Text] [Related]
14. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.
Rofo F; Meier SR; Metzendorf NG; Morrison JI; Petrovic A; Syvänen S; Sehlin D; Hultqvist G
Neurotherapeutics; 2022 Sep; 19(5):1588-1602. PubMed ID: 35939261
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
16. Passive and receptor mediated brain delivery of an anti-GFAP nanobody.
Meier SR; Sehlin D; Syvänen S
Nucl Med Biol; 2022; 114-115():121-127. PubMed ID: 35487832
[TBL] [Abstract][Full Text] [Related]
17. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1.
Webster CI; Caram-Salas N; Haqqani AS; Thom G; Brown L; Rennie K; Yogi A; Costain W; Brunette E; Stanimirovic DB
FASEB J; 2016 May; 30(5):1927-40. PubMed ID: 26839377
[TBL] [Abstract][Full Text] [Related]
18. A Perfused In Vitro Human iPSC-Derived Blood-Brain Barrier Faithfully Mimics Transferrin Receptor-Mediated Transcytosis of Therapeutic Antibodies.
Burgio F; Gaiser C; Brady K; Gatta V; Class R; Schrage R; Suter-Dick L
Cell Mol Neurobiol; 2023 Nov; 43(8):4173-4187. PubMed ID: 37698826
[TBL] [Abstract][Full Text] [Related]
19. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26.
Thom G; Burrell M; Haqqani AS; Yogi A; Lessard E; Brunette E; Delaney C; Baumann E; Callaghan D; Rodrigo N; Webster CI; Stanimirovic DB
Mol Pharm; 2018 Apr; 15(4):1420-1431. PubMed ID: 29485883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
